Clinical trials: Adjuvant Treatment
Head and Neck Cancer
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002702
- Testing
- aldesleukin, adjuvant therapy, conventional surgery
- Where
- 7 sites in Italy
- Volunteers
- 260 people
- Sponsor
- European Institute of Oncology
Endometrial Cancer
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II
Adjuvant radiotherapy (RT) plays an important role in reducing the risks of local recurrence after surgery in uterine cancers. Standard adjuvant pelvic radiation treatment targets the pelvic lymph nodes, the post-operative bed…
- Trial name
- SPARTACUSII (NCT04890912)
- Testing
- Conventional Fractionation, Hypofractionation
- Where
- 5 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Sunnybrook Health Sciences Centre
Melanoma Stage III, Melanoma Stage IV
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease
Currently, standard treatment options available for Stage III melanoma include locoregional management (i.e. surgery) or systemic treatment (adjuvant to surgery or primarily in the case of unresectable disease).
- Trial name
- NIVEC (NCT04330430)
- Testing
- T-VEC
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Nasopharyngeal Neoplasms
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
The objectives of this clinical study are threefold: 1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant…
- Trial name
- NCT00577057
- Testing
- Conventional Radiotherapy, Accelerated Radiotherapy, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 798 people
- Sponsor
- Hospital Authority, Hong Kong
Breast Cancer
Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients
This is an interventional, prospective and monocentric study. This study includes the evaluation before and after (neo)adjuvant therapy of : one group of patients receiving anthracyclines and taxanes a second group of patients…
- Trial name
- PROTECT-03 (NCT04638712)
- Testing
- Microbiopsy sample, Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Glaucoma, Acupuncture
Acupuncture as Adjuvant Therapy for Glaucoma - Protocol for a Randomized Controlled Trial
This clinical trial used acupuncture as an adjunctive treatment for glaucoma patients. A randomized, controlled trial involving 50 subjects will be conducted and observed for 12 weeks to evaluate the clinical efficacy of…
- Conditions
- Glaucoma, Acupuncture, Intraocular Pressure
- Trial name
- NCT05753137
- Testing
- Acupuncture
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return.
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Trial name
- NCT05642195
- Testing
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Patients With Resected Stage II Colon Cancer
CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
The objective of CIRCULATE trial is to improve care of patients after colon tumor surgery, based on an innovative marker: circulating tumor DNA.
- Trial name
- CIRCULATE (NCT04120701)
- Testing
- mFOLFOX6
- Where
- France
- Volunteers
- 1,980 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Breast Cancer
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil, and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01031030
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Volunteers
- 800 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Hepatocellular Carcinoma (HCC)
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical…
- Trial name
- NCT05213637
- Testing
- Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chinese PLA General Hospital
Muscle Invasive Bladder Cancer
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
- Trial name
- NIAGARA (NCT03732677)
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 1,063 people
- Sponsor
- AstraZeneca
Gastric Cancer
RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.
- Trial name
- NCT01401075
- Testing
- mistletoe extract, doxifluridine
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Abnoba Gmbh
Schizophrenia
Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.
- Trial name
- NCT00409201
- Testing
- reboxetine adjuvant therapy
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Abarbanel Mental Health Center
Breast Cancer, Breast-conserving Surgery
Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy
The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs.
- Trial name
- NCT05838001
- Testing
- Wire-guided localization and marker clip localization, marker clip localization
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
This is an open label, prospective, single center Phase II clinical study. Intended to evaluate the main pathological response rate (MPR) and safety of stereotactic immunosensitized radiotherapy combined with Evoximab…
- Trial name
- NCT06391008
- Testing
- Stereotactic radiotherapy, Evoximab, Pemetrexed
- Volunteers
- 44 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Breast Cancer
A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)
This is a randomized controlled study designed to evaluate the relapse-free survival of the UFT group compared with the CMF group.
- Trial name
- NCT00152191
- Testing
- UFT (uracil, tegafur), cyclophosphamide, methotrexate, and fluorouracil
- Where
- Japan
- Volunteers
- 1,300 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Early Stage Breast Carcinoma
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer
This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype…
- Trial name
- EXPERT (NCT02889874)
- Testing
- Omission of radiation therapy
- Where
- 68 sites in Argentina, Australia and 7 more
- Volunteers
- 1,167 people
- Sponsor
- Breast Cancer Trials, Australia and New Zealand
Amyotrophic Lateral Sclerosis (ALS)
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using…
- Trial name
- NCT07142291
- Testing
- Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg)
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 105 people
- Sponsor
- PhenoNet, Inc.
Breast Cancer
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
- Trial name
- NCT00556374
- Testing
- Denosumab, Non-steroidal aromatase inhibitor therapy, Zoledronic Acid
- Where
- 46 sites in Austria, Sweden
- Volunteers
- 3,420 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.